

Comprehensive Cancer Center

AACR 2020 Virtual Conference Session II June 22- 24, 2020

Full program: <u>https://www.aacr.org/meeting/aacr-annual-meeting-2020/virtual-meeting-ii-program/</u>

AACR News

Michelle Le Beau, **PhD**, Arthur and Marian Edelstein Professor of Medicine, Director of the University of Chicago Medicine Comprehensive Cancer Center is the 2020 recipient of the AACR – Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research.

Read the AACR press release <u>here</u>, At the Forefront article <u>here</u>, and the UChicago Medicine announcement <u>here</u>.

Events

June 23, 2020 5:15-6PM ET/4:15-5PM CT

AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research Lecture Therapy-related myeloid neoplasms: When genetics and environment collide Michelle Le Beau

Oral Presentations

June 23, 2020 9:20-30AM ET/8:20-30AM CT

Session MS.IM02.03 - Immunomodulatory Agents and Interventions 1072 - Lymphangiogenesis-inducing vaccines for melanoma treatment elicit potent tumorspecific T cell immunity and long-term tumor control Maria Stella Sasso...Melody Swartz.

June 23, 2020 9:20-30AM ET/8:20-30AM CT

Session MS.IM02.04 - Novel Immunotherapies and Mechanisms 5695 - Induction of lymphangiogenesis in breast cancer enhances responsiveness to immunotherapies Peyman Hosseinchi...Melody Swartz.

June 24, 2020 10:20-30AM ET/9:20-9:30 CT

Session MS.IM02.02 - Combination Immunotherapies 3417 - A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The small bowel tumor cohort Young Kwang Chae...Blase Polite...Razelle Kurzrock.

June 24, 2020 2:15-35PM ET/1:15-35PM CT

Session MW12 - Emerging Models: Bring in the Engineers In vitro models of the tumor-immune interface Melody Swartz.

June 24, 2020 5:30-50PM ET/4:30-50PM CT

Session ED37 - Radiation and Immunotherapy Radiotherapy and immunotherapy in oligometastatic disease Ralph Weichselbaum.

Poster Presentations

Available starting June 22, 2020 9AM/ET 8AM CT

Note: Links to PDFs of posters will be available through the AACR website and will be accompanied by an audio description.

Session PO.EP01.08 - Genetics, Genomics, Polygenic Score, and Risk Prediction 2320 / 4 - **Evaluating a polygenic risk score for breast cancer in women of African ancestry** Zhaohui Du... **Olufunmilayo Olopade**...Christopher A. Haiman.

Session PO.EP01.07 - Breast Cancer

4613 / 1 - Cross-ancestry genome-wide association study identifies six new loci for breast cancer in women of African and european ancestry Babatunde Adedokun...Olufunmilayo Olopade...Dezheng Huo.

Session PO.MCB05.01 - DNA Methylation 160 / 24 - Identifying differential methylation patterns of benign and tumor prostate tissue in African American and European American prostate cancer patients Meytal B. Chernoff...Brandon Pierce.

Session PO.PR03.01 - Implementation Science 5748 / 13 - Declines in health-related quality of life among older patients diagnosed with hematologic malignancies Ashwini Zolekar...Brian Chiu...Gregory S. Calip.

Session PO.EP01.04 - Integrative Genomics 28 / 1 - Integrating genomic and transcriptomic data to identify genetic loci associated with breast cancer risk in women of African ancestry Guochong Jia...Dezheng Huo...Olufunmilayo Olopade...Wei Zheng.

Session PO.IM02.16 - Immune Response to Therapies 1

5535 / 25 - SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors Haley Neff-LaFord...Thomas Gajewski...Andrew L. Coveler.

Session PO.CL01.04 - Tumor Type-focused Translational Research Specific 5451 / 29 - Longitudinal proteomic assessment of patient with metastatic apocrine adenocarcinoma reveals evolutionary selection for androgen-receptor-dependence and therapeutic response

Erik Dvergsten...Russell Szmulewitz, Michael L. Maitland.

Session PO.TB07.02 - Novel Tumor Imaging Techniques and Probes 1646 / 7 - **Preclinical oxygen imager for cancer oxygenation studies** Boris Epel, **Howard Halpern**, Mrignaayni Kotecha.

Session LBPO.TB03 - Late-Breaking Research: Tumor Biology 3 LB-370 / 22 - Whole-genome analysis of breast cancer patients from Nigeria reveals ethnicspecific evolution of somatic alterations and significant intratumoral heterogeneity Naser Ansari-Pour...Olufunmilayo Olopade.

Session VM2PO.CT01 - Phase I Clinical Trials

CT162 - The phase 1b PORTIA study: Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)

Ulrich Jaeger...Peter Riedell...Edmund K. Waller.

Session PO.IM02.13 - Immune Mechanisms Invoked by Therapies 2

2253 / 6 - Lymphangiogenesis augments the anti-tumor efficacy of radiotherapy in mouse melanoma

Nikolaos Mitrousis, Maria Stella Sasso, Ralph Weichselbaum...Melody Swartz.

Session PO.TB10.02 - Methods to Measure Tumor Evolution and Heterogeneity 2697 / 15 - Single cell RNA sequencing and tumor cell heterogeneity in metastatic triplenegative breast cancer

Dongbo Yang...Marsha Rosner.

Session PO.CL01.03 - New Technologies and Other Translational Studies 4263 / 17 - Characterization of patient-specific drug delivery for breast cancer using imageguided computational fluid dynamics

Chengyue Wu...Gregory S. Karczmar...Thomas E. Yankeelov.

Session PO.IM01.02 - Immunogenomics

4492 / 5 - Characterization of the T-Cell receptor repertoire in patients with acute myeloid leukemia treated with 5-Azacytidine plus chemotherapy John Beckford...Wendy Stock...Houda Alachkar.

Session PO.TB04.07 - Metastasis Therapies

5038 / 25 - Limited inhibition of multiple nodes in a driver network blocks metastasis

Ali Ekrem Yesilkanal...Marsha Rosner.

Session PO.BSB01.01 - Actionable Feature Detection in NGS and Omics 5468 / 16 - Gene fusions in breast cancer in Nigerian women Anna Elizabeth Woodard...Olufunmilayo Olopade.

Session PO.PR03.01 - Implementation Science 5749 / 14 - The association between physical health-related quality of life, physical functioning and risk of contralateral breast cancer Nita Mukand...Brian Chiu...Gregory S. Calip.

Session PO.TB07.03 - New Imaging-based Approaches to Plan, Monitor, and Augment Cancer Treatment

2773 / 5 - Increased tumor control boosting hypoxic regions identified with EPR pO2 imaging in 2 tumor types

Howard Halpern...Bulent Aydogan, Ralph Weichselbaum...Boris Epel.

Session PO.MCB04.01 - Gene Regulation and Transcription Factors 1 1290 / 13 - Role of NNMT-regulated m6A mRNA modification in triple-negative breast cancer oncogenic gene expression Deniz N. Dolcen...Chuan He, Suzanne D. Conzen.

Session PO.TB07.02 - Novel Tumor Imaging Techniques and Probes 1648 / 9 - **Multimodal imaging of tumor hypoxia with** ¹⁸F-misonidazole PET, EPR, and MRI Inna Gertsenshteyn...**Gregory Karczmar**...**Chin-Tu Chen, Howard Halpern**.

Session PO.IM02.03 - Adoptive Cell Therapy 3

 $3238\ /\ 10$ - Engineering chimeric antigen receptors for adoptive T cell therapy of cancers that express the Tn antigen

Preeti Sharma...Hans Schreiber, David M. Kranz.

Session PO.MCB08.05 - The Warburg Effect 5989 / 1 - **Metabolic heterogeneity of the tumor microenvironment** Bradley I. Reinfeld...**Alex Muir...**W. Kimryn Rathmell.

Session PO.ET01.02 - Novel Therapeutic Approaches 6428 / 22 - **Imputing a more selective therapy: Identifying Wee1 and XPO1 inhibitors for TNBC** Robert F. Gruener...**Geoffrey Greene**, R. Stephanie Huang.

Session PO.CH01.02 - Targeted Delivery of Small Molecules and Biologics 1

 $1729\ /\ 15$ - Novel liposomal topotecan formulation has a lower IC50 than the free form on neuroblastoma cells

Paula Viza Gomes...Jessica Kandel...Sonia L. Hernandez.

Session PO.EN02.01 - Molecular, Preclinical, and Clinical Endocrinology 2 4370 / 13 - Lasofoxifene alone or in combination with palbociclib as an effective treatment for therapy-resistant ER-positive metastatic breast cancer

Muriel Laine...Geoffrey Greene.

Session PO.EN02.01 - Molecular, Preclinical, and Clinical Endocrinology 2 4374 / 17 - **CE+BZA combination therapy decreases breast cancer outgrowth in part through activation of the AHR pathway** Anna G. Dembo...**Geoffrey Greene**.

Session PO.BSB01.06 - Tumor Heterogeneity and Microenvironment: Next-Generation Sequencing, Single Cell, and Imaging

4428 / 23 - Characterizing the tumor-infiltrating T-cell repertoire of breast cancer in indigenous African patients from Southwest Nigeria Jean-Baptiste Reynier...Olufunmilayo Olopade.

Session PO.IM02.22 - Vaccines

4582 / 22 - Tumor matrix-targeted polymeric glyco-adjuvant for in situ cancer vaccination Laura T. Gray...Melody Swartz, Jeffrey Hubbell.

Session PO.CL01.01 - Translational Research with Targeted Therapies 799 / 6 - **CDKN2A mutation predicts immunotherapy resistance in stage III/IV NSCLC** Stanley I. Gutiontov, **Sean Pitroda**.